Syndax Pharmaceuticals, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Syndax Pharmaceuticals, Inc. (SNDX) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $214.00 thousand as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-02-26
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $214.00K.
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $399.00K.
- 2023-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $189.00K.
- 2022-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $208.00K.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $214.00K 10-K · filed 2026-02-26 |
| 2024-12-31 | $399.00K 10-K · filed 2025-03-03 |
| 2023-12-31 | $189.00K 10-K · filed 2024-02-27 |
| 2022-12-31 | $208.00K 10-K · filed 2023-02-28 |
| 2021-12-31 | $231.00K 10-K · filed 2022-03-01 |
| 2020-12-31 | $36.00K 10-K · filed 2022-03-01 |
| 2019-12-31 | $141.00K 10-K · filed 2021-03-12 |
| 2019-09-30 | $177.00K 10-Q · filed 2019-11-07 |
| 2019-06-30 | $68.00K 10-Q · filed 2019-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |